REFERENCES
2. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2021;143:e72-227.
3. Vahanian A, Beyersdorf F, Praz F, et al.; ESC/EACTS Scientific Document Group. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2022;43:561-632.
4. Praz F, Borger MA, Lanz J, et al.; ESC/EACTS Scientific Document Group. 2025 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2025;46:4635-736.
5. Généreux P, Schwartz A, Oldemeyer JB, et al.; EARLY TAVR Trial Investigators. Transcatheter aortic-valve replacement for asymptomatic severe aortic stenosis. N Engl J Med. 2025;392:217-27.
6. Loganath K, Craig NJ, Everett RJ, et al.; EVOLVED investigators. Early intervention in patients with asymptomatic severe aortic stenosis and myocardial fibrosis: the EVOLVED randomized clinical trial. JAMA. 2025;333:213-21.
7. Kang DH, Park SJ, Lee SA, et al. Early surgery or conservative care for asymptomatic aortic stenosis. N Engl J Med. 2020;382:111-9.
8. Banovic M, Putnik S, Da Costa BR, et al. Aortic valve replacement vs. conservative treatment in asymptomatic severe aortic stenosis: long-term follow-up of the AVATAR trial. Eur Heart J. 2024;45:4526-35.
9. Jørgensen TH, Thyregod HGH, Savontaus M, et al.; NOTION-2 investigators. Transcatheter aortic valve implantation in low-risk tricuspid or bicuspid aortic stenosis: the NOTION-2 trial. Eur Heart J. 2024;45:3804-14.
10. Blankenberg S, Seiffert M, Vonthein R, et al.; DEDICATE-DZHK6 Trial Investigators. Transcatheter or surgical treatment of aortic-valve stenosis. N Engl J Med. 2024;390:1572-83.
11. Barbanti M, Costa G, Zappulla P, et al. Incidence of long-term structural valve dysfunction and bioprosthetic valve failure after transcatheter aortic valve replacement. J Am Heart Assoc. 2018;7:e008440.
12. Makkar RR, Thourani VH, Mack MJ, et al.; PARTNER 2 Investigators. Five-year outcomes of transcatheter or surgical aortic-valve replacement. N Engl J Med. 2020;382:799-809.
13. Sathananthan J, Lauck S, Polderman J, et al. Ten year follow-up of high-risk patients treated during the early experience with transcatheter aortic valve replacement. Catheter Cardiovasc Interv. 2021;97:E431-7.
14. Jørgensen TH, Thyregod HGH, Ihlemann N, et al. Eight-year outcomes for patients with aortic valve stenosis at low surgical risk randomized to transcatheter vs. surgical aortic valve replacement. Eur Heart J. 2021;42:2912-9.
15. Leon MB, Mack MJ, Pibarot P, et al.; PARTNER 3 Investigators. Transcatheter or surgical aortic-valve replacement in low-risk patients at 7 years. N Engl J Med. 2026;394:773-83.
16. Sá MP, Jacquemyn X, Van den Eynde J, et al. Midterm survival of low-risk patients treated with transcatheter versus surgical aortic valve replacement: meta-analysis of reconstructed time-to-event data. J Am Heart Assoc. 2023;12:e030012.
17. Krasniqi L, Brandes A, Mortensen PE, Gerke O, Riber L. Severe aortic stenosis treated with transcatheter aortic valve implantation or surgical aortic valve replacement with Perimount in Western Denmark 2016-2022: a nationwide retrospective study. Interdiscip Cardiovasc Thorac Surg. 2024;39:ivae122.
18. Biancari F, D’Errigo P, Barbanti M, et al. Ten-year outcomes after transcatheter or surgical aortic valve replacement in low-risk patients: the OBSERVANT study. Int J Cardiol Heart Vasc. 2024;55:101545.
19. Watanabe Y, Yamamoto M, Hioki H, et al.; OCEAN-TAVI Investigators. Long-term impact of mild paravalvular regurgitation after transcatheter aortic valve replacement: the OCEAN-TAVI registry. JACC Cardiovasc Interv. 2026;19:63-75.
20. Badertscher P, Stortecky S, Serban T, et al.; SwissTAVI Investigators. Long-term outcomes of patients requiring pacemaker implantation after transcatheter aortic valve replacement: the SwissTAVI registry. JACC Cardiovasc Interv. 2025;18:1163-71.
21. Jubran A, Patel RV, Sathananthan J, Wijeysundera HC. Lifetime management of patients with severe aortic stenosis in the era of transcatheter aortic valve replacement. Can J Cardiol. 2024;40:210-7.
22. Généreux P, Leon MB, Dar RD, et al. Predicting treatment of bioprosthetic aortic valve failure in the United States: a proposed model. Struct Heart. 2025;9:100339.
23. Bapat VN, Fukui M, Zaid S, et al. A guide to transcatheter aortic valve design and systematic planning for a redo-TAV (TAV-in-TAV) procedure. JACC Cardiovasc Interv. 2024;17:1631-51.
24. Testa L, Agnifili M, Van Mieghem NM, et al. Transcatheter aortic valve replacement for degenerated transcatheter aortic valves: the TRANSIT International Project. Circ Cardiovasc Interv. 2021;14:e010440.
25. Landes U, Webb JG, De Backer O, et al. Repeat transcatheter aortic valve replacement for transcatheter prosthesis dysfunction. J Am Coll Cardiol. 2020;75:1882-93.
26. Ochiai T, Oakley L, Sekhon N, et al. Risk of coronary obstruction due to sinus sequestration in redo transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2020;13:2617-27.
27. Forrestal BJ, Case BC, Yerasi C, et al. Risk of coronary obstruction and feasibility of coronary access after repeat transcatheter aortic valve replacement with the self-expanding evolut valve: a computed tomography simulation study. Circ Cardiovasc Interv. 2020;13:e009496.
28. Lederman RJ, Babaliaros VC, Rogers T, et al. Preventing coronary obstruction during transcatheter aortic valve replacement: from computed tomography to BASILICA. JACC Cardiovasc Interv. 2019;12:1197-216.
29. Mercanti F, Rosseel L, Neylon A, et al. Chimney stenting for coronary occlusion during TAVR: insights from the chimney registry. JACC Cardiovasc Interv. 2020;13:751-61.
30. Mangieri A, Gallo F, Popolo Rubbio A, et al. Outcome of coronary ostial stenting to prevent coronary obstruction during transcatheter aortic valve replacement. Circ Cardiovasc Interv. 2020;13:e009017.
31. Khan JM, Greenbaum AB, Babaliaros VC, et al. The BASILICA trial: prospective multicenter investigation of intentional leaflet laceration to prevent TAVR coronary obstruction. JACC Cardiovasc Interv. 2019;12:1240-52.
32. Rogers T, Khan JM, Laham R, et al.; TELLTALE Investigators. Electrosurgical leaflet modification to prevent coronary obstruction during transcatheter aortic valve replacement in failing native and bioprosthetic valves. JACC Cardiovasc Interv. 2025;18:2355-68.
33. Dvir D, Tchétché D, Leon MB, et al. Leaflet modification before transcatheter aortic valve implantation in patients at risk for coronary obstruction: the ShortCut study. Eur Heart J. 2024;45:3031-41.
34. Wong CK, Eric Chan KY, Chan DT, et al. UNICORN for valve-in-valve transcatheter aortic valve replacement: UNICORN Hong Kong Registry. JACC Asia. 2026;6:52-63.
35. Chan KE, Tai-Leung Chan D, Lam CS, et al. First-in-human undermining iatrogenic coronary obstruction with radiofrequency needle (UNICORN) procedure during valve-in-valve transcatheter aortic valve replacement. Circ Cardiovasc Interv. 2022;15:928-31.
36. Haberman D, Lupu L, Merdler I, et al. UNICORN with a self-expanding valve to treat a degenerated balloon-expandable valve. JACC Cardiovasc Interv. 2025;18:123-5.
37. TreSquare Technologies. Available from: https://tresquaretech.com/. [Last accessed on 30 Jun 2026].
38. Kharbanda RK, Kennedy J, Jamal Z, et al.; BHF PROTECT-TAVI Investigators. Routine cerebral embolic protection during transcatheter aortic-valve implantation. N Engl J Med. 2025;392:2403-12.
39. Kapadia SR, Makkar R, Leon M, et al.; PROTECTED TAVR Investigators. Cerebral embolic protection during transcatheter aortic-valve replacement. N Engl J Med. 2022;387:1253-63.
40. Jagielak D, Targonński R, Ciećwierz D. First-in-human use of the next-generation ProtEmbo cerebral embolic protection system during transcatheter aortic valve-in-valve implantation. Interv Cardiol. 2021;16:1-4.
41. Preda A, Montalto C, Galasso M, et al. Fighting cardiac thromboembolism during transcatheter procedures: an update on the use of cerebral protection devices in Cath Labs and EP Labs. Life. 2023;13:1819.
42. Van Gils L, Kroon H, Daemen J, et al. Complete filter-based cerebral embolic protection with transcatheter aortic valve replacement. Catheter Cardiovasc Interv. 2018;91:790-7.
